Trial intelligence / Profile preview

TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS

2014-004472-35Phase 2Completed

Sponsor
Leiden University Medical Center
Start
Dec 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2 trial of methotrexate and methylprednisolone in arthralgia, rheumatoid arthritis (RA) and Immune disorder, sponsored by Leiden University Medical Center. Primary endpoint: Progression to clinically apparent persistent arthritis. Started Dec 2014; status: completed.

02

Drugs

methotrexatemethylprednisolone
03

Conditions

arthralgiarheumatoid arthritis (RA)Immune disorder

Beyond the preview

Go deeper on 2014-004472-35.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2014-004472-35.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call